Panbela Therapeutics (PBLA) 10-Q 13 Aug 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 10, 2019
Document Information [Line Items]
Entity Registrant Name	Sun BioPharma, Inc.
Entity Central Index Key	0001029125
Trading Symbol	snbp
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		5,722,099
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash	$ 721	$ 1,405
Prepaid expenses and other current assets	93	110
Income tax receivable	474	332
Total current assets	1,288	1,847
Other noncurrent assets	51	51
Total assets	1,339	1,898
Current liabilities:
Accounts payable	289	1,064
Accrued expenses	192	212
Convertible notes payable, net of debt discounts		64
Term debt, current portion	232	286
Accrued interest	1	4
Total current liabilities	714	1,630
Unsecured promissory note payable	742
Total liabilities	1,456	1,630
Stockholders' (deficit) equity:
Preferred stock, $0.001 par value; 10,000,000 authorized; no shares issued or outstanding as of June 30, 2019 and December 31 2018	0	0
Common stock, $0.001 par value; 100,000,000 authorized; 5,722,099 and 5,077,483 shares issued and outstanding, as of June 30, 2019 and December 31, 2018, respectively	6	5
Additional paid-in capital	38,487	35,038
Accumulated deficit	(38,910)	(35,058)
Accumulated comprehensive income	300	283
Total stockholders' (deficit) equity	(117)	268
Total liabilities and stockholders' (deficit) equity	$ 1,339	$ 1,898

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	5,722,099	5,077,483
Common stock, shares outstanding (in shares)	5,722,099	5,077,483

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Operating expenses:
General and administrative	$ 580	$ 654	$ 883	$ 1,312
Research and development	508	442	858	1,024
Operating loss	(1,088)	(1,096)	(1,741)	(2,336)
Other (expense) income:
Grant income		12		22
Interest expense	(1,152)	(1,288)	(2,184)	(1,761)
Other (expense)	(101)	(192)	(68)	(273)
Total other expense	(1,253)	(1,468)	(2,252)	(2,012)
Loss before income tax benefit	(2,341)	(2,564)	(3,993)	(4,348)
Income tax benefit	70	79	141	108
Net loss	(2,271)	(2,485)	(3,852)	(4,240)
Foreign currency translation adjustment	49	101	17	169
Comprehensive loss	$ (2,222)	$ (2,384)	$ (3,835)	$ (4,071)
Basic and diluted net loss per share (in dollars per share)	$ (0.45)	$ (0.54)	$ (0.76)	$ (1)
Weighted average shares outstanding - basic and diluted (in shares)	5,070,341	4,570,601	5,071,378	4,248,603

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balances (in shares) at Dec. 31, 2017	3,842
Balances at Dec. 31, 2017	$ 4	$ 25,625	$ (29,153)	$ (165)	$ (3,689)
Sale of common stock and warrants (in shares)	252
Sale of common stock and warrants		1,261			1,261
Stock-based compensation		1,792			1,792
Net loss			(1,753)		(1,753)
Foreign currency translation adjustment				69	69
Balances (in shares) at Mar. 31, 2018	4,094
Balances at Mar. 31, 2018	$ 4	28,678	(30,906)	(96)	(2,320)
Balances (in shares) at Dec. 31, 2017	3,842
Balances at Dec. 31, 2017	$ 4	25,625	(29,153)	(165)	(3,689)
Net loss					(4,240)
Foreign currency translation adjustment					169
Warrants issued with sale of convertible notes payable
Common stock converted into convertible notes payable
Balances (in shares) at Jun. 30, 2018	5,061
Balances at Jun. 30, 2018	$ 5	33,494	(33,393)	4	110
Balances (in shares) at Mar. 31, 2018	4,094
Balances at Mar. 31, 2018	$ 4	28,678	(30,906)	(96)	(2,320)
Sale of common stock and warrants (in shares)	216
Sale of common stock and warrants		1,080			1,080
Stock-based compensation		358			358
Net loss			(2,487)		(2,485)
Foreign currency translation adjustment				100	101
Beneficial conversion feature		121			121
Conversion of convertible notes payable and accrued interest into common stock and warrants (in shares)	751
Conversion of convertible notes payable and accrued interest into common stock and warrants	$ 1	3,257			3,258
Balances (in shares) at Jun. 30, 2018	5,061
Balances at Jun. 30, 2018	$ 5	33,494	(33,393)	4	110
Balances (in shares) at Dec. 31, 2018	5,077
Balances at Dec. 31, 2018	$ 5	35,038	(35,058)	283	268
Stock-based compensation		10			10
Net loss			(1,581)		(1,581)
Foreign currency translation adjustment				(32)	(32)
Beneficial conversion feature		353			353
Warrants issued with sale of convertible notes payable		419			419
Common stock converted into convertible notes payable (in shares)	(7)
Common stock converted into convertible notes payable		(25)			(25)
Balances (in shares) at Mar. 31, 2019	5,070
Balances at Mar. 31, 2019	$ 5	35,795	(36,639)	251	(588)
Balances (in shares) at Dec. 31, 2018	5,077
Balances at Dec. 31, 2018	$ 5	35,038	(35,058)	283	268
Net loss					(3,852)
Foreign currency translation adjustment					17
Warrants issued with sale of convertible notes payable					419
Common stock converted into convertible notes payable					(25)
Balances (in shares) at Jun. 30, 2019	5,722
Balances at Jun. 30, 2019	$ 6	38,487	(38,910)	300	(117)
Balances (in shares) at Mar. 31, 2019	5,070
Balances at Mar. 31, 2019	$ 5	35,795	(36,639)	251	(588)
Stock-based compensation		412			412
Net loss			(2,271)		(2,271)
Foreign currency translation adjustment				49	49
Conversion of convertible notes payable and accrued interest into common stock and warrants (in shares)	652
Conversion of convertible notes payable and accrued interest into common stock and warrants	$ 1	2,280			2,281
Balances (in shares) at Jun. 30, 2019	5,722
Balances at Jun. 30, 2019	$ 6	$ 38,487	$ (38,910)	$ 300	$ (117)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash flows from operating activities:
Net loss	$ (3,852,000)	$ (4,240,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	422,000	1,056,000
Amortization of debt discount	2,061,000	1,687,000
Amortization of debt issuance costs	12,000	9,000
Non-cash interest expense	102,000	43,000
Changes in operating assets and liabilities:
Income tax receivable	(144,000)	(106,000)
Prepaid expenses and other current assets	17,000	53,000
Accounts payable	(12,000)	(67,000)
Accrued liabilities	(20,000)	(20,000)
Net cash used in operating activities	(1,414,000)	(1,585,000)
Cash flows from financing activities:
Proceeds from the sale of convertible promissory notes and warrants, net of debt issuance costs of $7	810,000
Proceeds from sale of common stock and warrants, net of offering costs of $27		2,341,000
Repayment of demand note	(25,000)
Repayments of term debt	(55,000)
Net cash provided by financing activities	730,000	2,341,000
Effect of exchange rate changes on cash		(3,000)
Net change in cash	(684,000)	753,000
Cash at beginning of period	1,405,000	152,000
Cash at end of period	721,000	905,000
Supplemental disclosure of cash flow information:
Cash paid during period for interest	8,000	22,000
Supplemental disclosure of non-cash transactions:
Beneficial conversion feature on convertible notes	353,000	121,000
Warrants issued with convertible notes	419,000
Common stock converted into convertible notes payable	25,000
Conversion of convertible notes payable and accrued interest into common stock and warrants		2,908,000
Conversion of convertible notes payable and accrued interest into common stock	2,281,000	350,000
Issuance of unsecured promissory note in exchange for vendor accounts payable	742,000
Options granted in exchange for release from contingent payment obligations		$ 1,094,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Proceeds from the sale of convertible promissory notes, offering costs	$ 7
Proceeds from issuance of common stock and warrants, issuance costs		$ 27

Note 1 - Business

Note 1 - Business	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Business Sun BioPharma, Inc. together with its wholly-owned subsidiary Sun BioPharma Australia Pty Ltd. (collectively “we,” “us,” “our,” and the “Company”), exists for the primary purpose of advancing the commercial development of a proprietary polyamine analogue (the “compound”) for the treatment of patients with pancreatic cancer and for a potential second 101,

Note 2 - Risks and Uncertaintie

Note 2 - Risks and Uncertainties	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Nature of Operations [Text Block]	2. Risks and Uncertainties The Company operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (“FDA”) in the United States, the Therapeutic Goods Administration in Australia, the European Medicines Agency in the European Union, and comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may We have incurred losses of $38.9 2011. six June 30, 2019, $3.9 $2.1 $1.4 $0.8 4 January 2019, December 2018 June 30, 2019. 101, June 30, 2019, $0.7 $0.6 $0.1 The accompanying condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The condensed not 2018 March 22, 2019. 101 101 4

Note 3 - Basis of Presentation

Note 3 - Basis of Presentation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	3. Basis of Presentation We have prepared the accompanying interim condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10 X not December 31. December 31, 2018 not 10 may not Recently Adopted Accounting Pronouncement s In June 2018, 2018 07, 718 2018 07 January 1, 2019. In February 2016, 2016 02, 842 12 not January 1, 2019. no no one

Note 4 - Liquidity and Business

Note 4 - Liquidity and Business Plan	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	4. Liquidity and Business Plan We will need to obtain additional funds to continue our operations and execute our current business plans. We may no not In closings occurring in December 2018 January 2019 $2.2 1,243,498 June 30, 2019 $105,000 651,758 $3.50. 6 five $4.50. If we are unable to obtain additional financing when needed, we believe that will need to reduce our operations by taking actions that may 101 third 101 Our future success is dependent upon our ability to obtain additional financing, the success of our development efforts, our ability to obtain marketing approval for our SBP- 101 101 not not There can be no

Note 5 - Summary of Significant

Note 5 - Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	5. Summary of Significant Accounting Policies Principles of consolidation The accompanying condensed consolidated financial statements include the assets, liabilities and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation. Use of estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates. Beneficial c onversion f eatures For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a beneficial conversion feature and related debt discount that is presented as a direct deduction from the carrying amount of the related debt and as an increase to additional paid-in capital. The debt discount is amortized through interest expense over the life of the related debt. Debt issuance costs Costs associated with the issuance of debt instruments are capitalized and presented as a direct deduction from the carrying amount of the related debt liability. These costs are amortized through interest expense over the life of the related debt. Research and development costs Research and development costs include expenses incurred in the conduct of our second Phase 1 human clinical trial, for third -party service providers performing various testing and accumulating data related to our preclinical studies; sponsored research agreements; developing and scaling the manufacturing process necessary to produce sufficient amounts of the SBP- 101 compound for use in our pre-clinical studies and human clinical trials; consulting resources with specialized expertise related to execution of our development plan for our SBP- 101 product candidate; personnel costs, including salaries, benefits and share-based compensation; and costs to license and maintain our licensed intellectual property. We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no alternative future use of the intellectual property subject to the license. Stock-based compensation In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not expect to declare any dividends in the foreseeable future. The expected term of options granted is determined using the “simplified” method. Under this approach, the expected term is presumed to be the mid-point between the average vesting date and the end of the contractual term. Forfeitures of unvested stock options are recognized as they occur. Foreign currency translation adjustments The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the statements of stockholders’ equity (deficit). During the six -month periods ended June 30, 2019 and 2018, any reclassification adjustments from accumulated other comprehensive loss to operations were inconsequential. Comprehensive loss Comprehensive loss consists of our net loss and the effects of foreign currency translation. Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include convertible debt, outstanding common stock options, and warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive. The following table sets forth the potential shares of common stock that were not included in the calculation of diluted net loss per share as their effects would have been anti-dilutive as of: June 30, 2019 2018 Employee and non-employee stock options 1,552,211 1,137,960 Estimated common shares issuable upon conversion of notes payable and accrued interest - 2,222 Common stock issuable under common stock purchase warrants 2,509,477 1,265,979 4,061,688 2,406,161

Note 6 - Indebtedness

Note 6 - Indebtedness	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	6 . Indebtedness Notes On June 30, 2019, $2.2 $105,000 $3.50 651,758 December 2018 January 2019 10.0% June 30, 2019. Term debt Effective April 5, 2019 May 1, 2019 December 31, 2019. 5,555 $4.50. five not $10,000. June 30, 2019 $232,000. Unsecured Promissory Notes On May 17, 2019 $742,000 not 1 December 31, 2020 2

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	7 . S tock holders’ Deficit Shares of common stock reserved for future issuance were as follows as of June 3 0 , 2019: Total Reserved Stock options outstanding 1,552,211 Shares available for grant under equity incentive plan 212,149 Common shares issuable under outstanding common stock purchase warrants 2,509,477 4,273,837

Note 8 - Stock-based Compensati

Note 8 - Stock-based Compensation	6 Months Ended
	Jun. 30, 2019
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	8 . S tock -based Compensation 2016 The Sun BioPharma, Inc. 2016 “2016 March 2016 May 2016. 2016 2016 no 2016 ten 2016 1,500,000 June 30, 2019, 1,285,711 2016 212,149 2011 Our Board of Directors ceased making awards under the Sun BioPharma, Inc. 2011 “2011 2016 2011 2011 ten zero two June 30, 2019, 266,500 2011 Stock -based Compensation Expense General and administrative (“G&A”) and research and development (“R&D”) expenses include non-cash stock-based compensation expense as a result of our issuance of stock options. The terms and vesting schedules for stock-based awards vary by type of grant and the employment status of the grantee. The awards granted through June 30, 2019 $0.6 June 30, 2019. Stock-based compensation expense for each of the periods presented is as follows (in thousands): Six Months Ended June 30, 2019 2018 General and Administrative $ 260 $ 1,315 Research and Development 162 835 $ 422 $ 2,150 A summary of stock option activity for the six June 30, 2019 Shares Available for Grant Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at December 31, 2018 732,149 1,032,211 $ 8.90 $ 169,495 Granted (540,800 ) 540,800 2.95 Exercised - - - Cancelled - - - Forfeitures 20,800 (20,800 ) 15.10 Balance at June 30, 2019 212,149 1,552,211 $ 6.75 $ 32,195 Information about stock options outstanding, vested and expected to vest as of June 30, 2019, Outstanding, Vested and Expected to Vest Options Vested and Excercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Excercisable Weighted Average Remaining Contractual Life (Years) $0.875 - $1.10 26,360 3.50 $ 0.875 26,360 3.50 $2.275 - $2.50 38,000 4.62 $ 2.464 38,000 4.62 $2.950 540,800 9.89 $ 2.950 198,125 9.89 $3.175 200,000 5.68 $ 3.175 200,000 5.68 $5.75 - $8.10 379,000 7.75 $ 7.488 349,000 7.69 $10.00 - $10.10 54,000 8.06 $ 10.007 54,000 8.06 $15.10 314,051 6.91 $ 15.100 307,051 7.01 Totals 1,552,211 7.92 $ 6.746 1,182,536 7.37 Key assumptions The estimated grant-date fair values of the stock options were calculated using the Black-Scholes valuation model, based on the following assumptions for the three June 30, 2019: 2019 Common stock fair value $ 2.95 Risk-free interest rate 2.25% Expected dividend yield 0% Expected Option life (in years) 5.50 Expected stock price volatility 72%

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of consolidation The accompanying condensed consolidated financial statements include the assets, liabilities and expenses of the Company. All significant intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Actual results could differ from those estimates.
Beneficial Conversion Feature, Policy [Policy Text Block]	Beneficial c onversion f eatures For convertible debt where the rate of conversion is below fair market value for our common stock, the Company records a beneficial conversion feature and related debt discount that is presented as a direct deduction from the carrying amount of the related debt and as an increase to additional paid-in capital. The debt discount is amortized through interest expense over the life of the related debt.
Debt Issuance Costs [Policy Text Block]	Debt issuance costs Costs associated with the issuance of debt instruments are capitalized and presented as a direct deduction from the carrying amount of the related debt liability. These costs are amortized through interest expense over the life of the related debt.
Research and Development Expense, Policy [Policy Text Block]	Research and development costs Research and development costs include expenses incurred in the conduct of our second 1 third 101 101 We charge research and development costs, including clinical trial costs, to expense when incurred. Our human clinical trials are, and will be, performed at clinical trial sites and are administered jointly by us with assistance from contract research organizations (“CROs”). Costs of setting up clinical trial sites are accrued upon execution of the study agreement. Expenses related to the performance of clinical trials generally are accrued based on contracted amounts and the achievement of agreed upon milestones, such as patient enrollment, patient follow-up, etc. We monitor levels of performance under each significant contract, including the extent of patient enrollment and other activities through communications with the clinical trial sites and CROs, and adjust the estimates, if required, on a quarterly basis so that clinical expenses reflect the actual effort expended at each clinical trial site and by each CRO. All material CRO contracts are terminable by us upon written notice and we are generally only liable for actual effort expended by the CROs and certain non-cancelable expenses incurred at any point of termination. We expense costs associated with obtaining licenses for patented technologies when it is determined there is no
Share-based Payment Arrangement [Policy Text Block]	Stock-based compensation In accounting for stock-based incentive awards, we measure and recognize the cost of employee and non-employee services received in exchange for awards of equity instruments based on the fair value of those awards on the grant date. Calculating stock-based compensation expense requires the input of highly subjective assumptions, which represent our best estimates and involve inherent uncertainties and the application of management’s judgment. Compensation cost is recognized ratably using the straight-line attribution method over the vesting period, which is considered to be the requisite service period. Compensation expense for performance-based stock option awards is recognized when “performance” has occurred or is probable of occurring. The fair value of stock-based awards is estimated at the date of grant using the Black-Scholes option pricing model. The determination of the fair value of stock-based awards is affected by our stock price, as well as assumptions regarding a number of complex and subjective variables. Risk free interest rates are based upon U.S. Treasury rates appropriate for the expected term of each award. Expected volatility rates are based primarily on the volatility rates of a set of guideline companies, which consist of public and recently public biotechnology companies. The assumed dividend yield is zero, as we do not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation adjustments The functional currency of Sun BioPharma Australia Pty Ltd is the Australian Dollar. Accordingly, assets and liabilities, and equity transactions of Sun BioPharma Australia Pty Ltd are translated into U.S. dollars at period-end exchange rates. Revenues and expenses are translated at the average exchange rate in effect for the period. The resulting translation gains and losses are recorded as a component of accumulated comprehensive loss presented within the statements of stockholders’ equity (deficit). During the six June 30, 2019 2018,
Comprehensive Income, Policy [Policy Text Block]	Comprehensive loss Comprehensive loss consists of our net loss and the effects of foreign currency translation.
Earnings Per Share, Policy [Policy Text Block]	Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted average of common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be anti-dilutive or reduce a net loss per share. The Company’s potential dilutive shares, which include convertible debt, outstanding common stock options, and warrants, have not The following table sets forth the potential shares of common stock that were not June 30, 2019 2018 Employee and non-employee stock options 1,552,211 1,137,960 Estimated common shares issuable upon conversion of notes payable and accrued interest - 2,222 Common stock issuable under common stock purchase warrants 2,509,477 1,265,979 4,061,688 2,406,161

Note 5 - Summary of Significa_2

Note 5 - Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	June 30, 2019 2018 Employee and non-employee stock options 1,552,211 1,137,960 Estimated common shares issuable upon conversion of notes payable and accrued interest - 2,222 Common stock issuable under common stock purchase warrants 2,509,477 1,265,979 4,061,688 2,406,161

Note 7 - Stockholders' Deficit

Note 7 - Stockholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Schedule of Common Stock Reserved for Future Issuance [Table Text Block]	Total Reserved Stock options outstanding 1,552,211 Shares available for grant under equity incentive plan 212,149 Common shares issuable under outstanding common stock purchase warrants 2,509,477 4,273,837

Note 8 - Stock-based Compensa_2

Note 8 - Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Six Months Ended June 30, 2019 2018 General and Administrative $ 260 $ 1,315 Research and Development 162 835 $ 422 $ 2,150
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Shares Available for Grant Shares Underlying Options Weighted Average Exercise Price Per Share Aggregate Intrinsic Value Balance at December 31, 2018 732,149 1,032,211 $ 8.90 $ 169,495 Granted (540,800 ) 540,800 2.95 Exercised - - - Cancelled - - - Forfeitures 20,800 (20,800 ) 15.10 Balance at June 30, 2019 212,149 1,552,211 $ 6.75 $ 32,195
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Outstanding, Vested and Expected to Vest Options Vested and Excercisable Per Share Exercise Price Shares Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Options Excercisable Weighted Average Remaining Contractual Life (Years) $0.875 - $1.10 26,360 3.50 $ 0.875 26,360 3.50 $2.275 - $2.50 38,000 4.62 $ 2.464 38,000 4.62 $2.950 540,800 9.89 $ 2.950 198,125 9.89 $3.175 200,000 5.68 $ 3.175 200,000 5.68 $5.75 - $8.10 379,000 7.75 $ 7.488 349,000 7.69 $10.00 - $10.10 54,000 8.06 $ 10.007 54,000 8.06 $15.10 314,051 6.91 $ 15.100 307,051 7.01 Totals 1,552,211 7.92 $ 6.746 1,182,536 7.37
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2019 Common stock fair value $ 2.95 Risk-free interest rate 2.25% Expected dividend yield 0% Expected Option life (in years) 5.50 Expected stock price volatility 72%

Note 2 - Risks and Uncertaint_2

Note 2 - Risks and Uncertainties (Details Textual) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended		102 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Net Income (Loss) Attributable to Parent, Total	$ (2,271)	$ (1,581)	$ (2,485)	$ (1,753)	$ (3,852)	$ (4,240)	$ (38,900)
Amortization of Debt Discount (Premium)					2,061	1,687
Net Cash Provided by (Used in) Operating Activities, Total					(1,414)	(1,585)
Proceeds from Issuance or Sale of Equity, Total					800
Cash and Cash Equivalents, at Carrying Value, Ending Balance	721		905		721	905	721	$ 1,405	$ 152
Working Capital	600				600		600
Stockholders' Equity Attributable to Parent, Ending Balance	$ (117)	$ (588)	$ 110	$ (2,320)	$ (117)	$ 110	$ (117)	$ 268	$ (3,689)

Note 4 - Liquidity and Busine_2

Note 4 - Liquidity and Business Plan (Details Textual) - USD ($)	Jun. 30, 2019	Jan. 31, 2019	Jun. 30, 2019	Jun. 30, 2018
Proceeds from Convertible Debt			$ 810,000
Conversion from Debt to Common Stock [Member]
Debt Conversion, Accrued Interest, Amount	$ 105,000
Debt Conversion, Converted Instrument, Shares Issued	651,758
Debt Instrument, Convertible, Conversion Price	$ 3.50		$ 3.50
Warrants In Connection with 2018 Convertible Notes Payable [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,243,498
Warrants in Connection with Securities Purchase Agreement [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.50		$ 4.50
Unsecured Convertible Promissory Notes [Member]
Proceeds from Convertible Debt		$ 2,200,000

Note 5 - Summary of Significa_3

Note 5 - Summary of Significant Accounting Policies - Anti-dilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Anti-dilutive securities (in shares)	4,061,688	2,406,161
Share-based Payment Arrangement [Member]
Anti-dilutive securities (in shares)	1,552,211	1,137,960
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)		2,222
Warrant [Member]
Anti-dilutive securities (in shares)	2,509,477	1,265,979

Note 6 - Indebtedness (Details

Note 6 - Indebtedness (Details Textual) - USD ($)	Jun. 30, 2019	May 17, 2019	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Increase (Decrease) in Accounts Payable, Total		$ 742,000	$ (12,000)	$ (67,000)
Unsecured Long-term Debt, Noncurrent	$ 742,000		$ 742,000
Warrants In Connection with Term Debt [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	5,555		5,555
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 4.50		$ 4.50
Warrants and Rights Outstanding, Term	5 years		5 years
Term Debt [Member]
Debt Instrument, Periodic Payment, Total			$ 10,000
Long-term Debt, Total	$ 232,000		$ 232,000
Unsecured Promissory Note [Member]
Unsecured Long-term Debt, Noncurrent		$ 742,000
Convertible Debt [Member] | The 2018 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage	10.00%		10.00%
Conversion from Debt to Common Stock [Member]
Debt Conversion, Original Debt, Amount	$ 2,200,000
Debt Conversion, Accrued Interest, Amount	$ 105,000
Debt Instrument, Convertible, Conversion Price	$ 3.50		$ 3.50
Debt Conversion, Converted Instrument, Shares Issued	651,758

Note 7 - Stockholders' Defici_2

Note 7 - Stockholders' Deficit - Common Stock Reserved for Future Issuance (Details) - shares	Jun. 30, 2019	Dec. 31, 2018
Stock options outstanding (in shares)	1,552,211
Shares available for grant under equity incentive plan (in shares)	212,149	732,149
Common shares issuable under outstanding common stock purchase warrants (in shares)	2,509,477
(in shares)	4,273,837

Note 8 - Stock-based Compensa_3

Note 8 - Stock-based Compensation (Details Textual) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Common Stock, Capital Shares Reserved for Future Issuance	4,273,837
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	1,552,211	1,032,211
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 0.6
Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Common Stock, Capital Shares Reserved for Future Issuance	212,149
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	1,285,711
Sun BioPharma, Inc. 2016 Omnibus Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Common Stock, Capital Shares Reserved for Future Issuance	1,500,000
Sun BioPharma, Inc. 2011 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	266,500
Sun BioPharma, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	0 years
Sun BioPharma, Inc. 2011 Stock Option Plan [Member] | Share-based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	2 years

Note 8 - Stock-based Compensa_4

Note 8 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Share-based compensation expense	$ 422	$ 2,150
General and Administrative Expense [Member]
Share-based compensation expense	260	1,315
Research and Development Expense [Member]
Share-based compensation expense	$ 162	$ 835

Note 8 - Stock-based Compensa_5

Note 8 - Stock-based Compensation - Summary of Option Activity (Details) - USD ($)	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Balance, shares available for grant (in shares)	732,149
Balance, shares underlying options (in shares)	1,032,211
Balance, weighted average exercise price per share (in dollars per share)	$ 6.75	$ 8.90
Aggregate intrinsic value	$ 32,195	$ 169,495
Granted, shares available for grant (in shares)	(540,800)
Granted, shares underlying options (in shares)	540,800
Granted, weighted average exercise price per share (in dollars per share)	$ 2.95
Excercised, shares underlying options (in shares)
Forfeitures , shares available for grant (in shares)	20,800
Forfeited, shares underlying options (in shares)	(20,800)
Forfeited, weighted average exercise price per share (in dollars per share)	$ 15.10
Balance, shares available for grant (in shares)	212,149
Balance, shares underlying options (in shares)	1,552,211

Note 8 - Stock-based Compensa_6

Note 8 - Stock-based Compensation - Options Outstanding (Details)	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Options outstanding (in shares) | shares	1,552,211
Options outstanding, weighted average remaining contractual life (Year)	7 years 335 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 6.746
Options excercisable (in shares) | shares	1,182,536
Options excercisable, weighted average remaining contractual life (Year)	7 years 135 days
Exercise Price Range 1 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 0.875
Per share exercise price, upper limit (in dollars per share)	$ 1.10
Options outstanding (in shares) | shares	26,360
Options outstanding, weighted average remaining contractual life (Year)	3 years 182 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 0.875
Options excercisable (in shares) | shares	26,360
Options excercisable, weighted average remaining contractual life (Year)	3 years 182 days
Exercise Price Range 2 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.275
Per share exercise price, upper limit (in dollars per share)	$ 2.50
Options outstanding (in shares) | shares	38,000
Options outstanding, weighted average remaining contractual life (Year)	4 years 226 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.464
Options excercisable (in shares) | shares	38,000
Options excercisable, weighted average remaining contractual life (Year)	4 years 226 days
Exercise Price Range 3 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 2.95
Per share exercise price, upper limit (in dollars per share)	$ 2.95
Options outstanding (in shares) | shares	540,800
Options outstanding, weighted average remaining contractual life (Year)	9 years 324 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 2.95
Options excercisable (in shares) | shares	198,125
Options excercisable, weighted average remaining contractual life (Year)	9 years 324 days
Exercise Price Range 4 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 3.175
Per share exercise price, upper limit (in dollars per share)	$ 3.175
Options outstanding (in shares) | shares	200,000
Options outstanding, weighted average remaining contractual life (Year)	5 years 248 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.175
Options excercisable (in shares) | shares	200,000
Options excercisable, weighted average remaining contractual life (Year)	5 years 248 days
Exercise Price Range 5 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 5.75
Per share exercise price, upper limit (in dollars per share)	$ 8.10
Options outstanding (in shares) | shares	379,000
Options outstanding, weighted average remaining contractual life (Year)	7 years 273 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 7.488
Options excercisable (in shares) | shares	349,000
Options excercisable, weighted average remaining contractual life (Year)	7 years 251 days
Exercise Price Range 6 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 10
Per share exercise price, upper limit (in dollars per share)	$ 10.10
Options outstanding (in shares) | shares	54,000
Options outstanding, weighted average remaining contractual life (Year)	8 years 21 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 10.007
Options excercisable (in shares) | shares	54,000
Options excercisable, weighted average remaining contractual life (Year)	8 years 21 days
Exercise Price Range 7 [Member]
Per share exercise price, lower limit (in dollars per share)	$ 15.10
Per share exercise price, upper limit (in dollars per share)	$ 15.1
Options outstanding (in shares) | shares	314,051
Options outstanding, weighted average remaining contractual life (Year)	6 years 332 days
Options outstanding, weighted average exercise price (in dollars per share)	$ 15.1
Options excercisable (in shares) | shares	307,051
Options excercisable, weighted average remaining contractual life (Year)	7 years 3 days

Note 8 - Stock-based Compensa_7

Note 8 - Stock-based Compensation - Assumptions Used in Calculating Fair Value of Options (Details)	3 Months Ended
	Jun. 30, 2019$ / shares
Common stock fair value (in dollars per share)	$ 2.95
Risk-free interest rate	2.25%
Expected dividend yield	0.00%
Expected Option life (in years) (Year)	5 years 182 days
Expected stock price volatility	72.00%